In Q2 concall they said, post capacity they can do peak revenue of 1200 Cr. Even if i assume 18% margins, EBITDA would be 216 Cr.
For new capacity utilization would be 60% in FY25. May see optimum utilization by FY26. So EBITDA will double in next 3-4 years. Debt will also increase which will impact bottom line. So PAT may be double which looks priced in already
Please correct me if i am missing something.
Management commentary was hawkish for H2FY23 due to US and Europe slowdown. Apart from that there are other strong players like NOCIL, CAMLIN, Clean science.
Someone on the call asked the management about their edge against the competition, his answer was ” see my result, it has been growing so i am more competitive”.
I can’t find any competitive advantage for the company. If someone have read NOCI, clean science or any other peers. Please update us here.
| Subscribe To Our Free Newsletter |
